{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:13:38Z","timestamp":1772165618031,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T00:00:00Z","timestamp":1612742400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T00:00:00Z","timestamp":1612742400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012319","name":"National Center for Global Health and Medicine","doi-asserted-by":"publisher","award":["30-shi-2001"],"award-info":[{"award-number":["30-shi-2001"]}],"id":[{"id":"10.13039\/100012319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012319","name":"National Center for Global Health and Medicine","doi-asserted-by":"publisher","award":["20A1002"],"award-info":[{"award-number":["20A1002"]}],"id":[{"id":"10.13039\/100012319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012319","name":"National Center for Global Health and Medicine","doi-asserted-by":"publisher","award":["30-shi-1011"],"award-info":[{"award-number":["30-shi-1011"]}],"id":[{"id":"10.13039\/100012319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["19fk0210058h0001"],"award-info":[{"award-number":["19fk0210058h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["20fk0210058h0002"],"award-info":[{"award-number":["20fk0210058h0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Pathological angiogenesis is involved in the development of hepatocellular carcinoma. In patients with chronic hepatitis C (CHC), the level of angiogenic factor angiopoietin (ANGP)-2 is reported to be increased in the blood, correlating with fibrosis. In this study, we aimed to clarify whether blood ANGP-2 is useful as a biomarker for liver angiogenesis and fibrosis in CHC patients and to further reveal the relationship between such pathology in a carbon tetrachloride (CCl\n                      <jats:sub>4<\/jats:sub>\n                      )-treated liver fibrosis mouse model.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Plasma levels of ANGP-2, expression of a liver sinusoidal endothelial cell (LSEC) marker (CD31), collagen deposition (Sirius Red staining) in the liver, clinical fibrosis markers (Mac-2 binding protein glycosylation isomer, virtual touch quantification, and liver stiffness measurement), and liver function (albumin bilirubin score) were examined in CHC patients. To determine the effects of an anti-angiogenic agent on liver fibrosis in vivo, sorafenib was administered to the CCl\n                      <jats:sub>4<\/jats:sub>\n                      -treated mice (BALB\/c male).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The plasma levels of ANGP-2 were increased in CHC patients compared to healthy volunteers and decreased by the eradication of hepatitis C with direct-acting antivirals. In addition, plasma ANGP-2 levels were correlated with CD31 expression, collagen deposition, clinical fibrosis markers, and liver function. Sorafenib inhibited liver angiogenesis and fibrosis in the CCl\n                      <jats:sub>4<\/jats:sub>\n                      -treated mice and was accompanied by decreased ANGP-2 expression in LSECs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ANGP-2 may serve as a useful biomarker for liver angiogenesis and fibrosis in CHC patients. In addition, angiogenesis and fibrosis may be closely related.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-021-01633-8","type":"journal-article","created":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T17:50:31Z","timestamp":1612806631000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Blood angiopoietin-2 predicts liver angiogenesis and fibrosis in hepatitis C patients"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3581-1009","authenticated-orcid":false,"given":"Yosuke","family":"Osawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachiyo","family":"Yoshio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiko","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Korenaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Oide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miku","family":"Okawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironari","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuriko","family":"Tsutsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiori","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taizo","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taiji","family":"Yamazoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Kanto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,8]]},"reference":[{"issue":"3","key":"1633_CR1","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1002\/hep.30294","volume":"69","author":"S Lefere","year":"2019","unstructured":"Lefere S, Van de Velde F, Hoorens A, Raevens S, Van Campenhout S, Vandierendonck A, Neyt S, Vandeghinste B, Vanhove C, Debbaut C, et al. Angiopoietin-2 promotes pathological angiogenesis and is a therapeutic target in murine nonalcoholic fatty liver disease. Hepatology. 2019;69(3):1087\u2013104.","journal-title":"Hepatology"},{"issue":"12","key":"1633_CR2","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1038\/nmat5024","volume":"16","author":"L Liu","year":"2017","unstructured":"Liu L, You Z, Yu H, Zhou L, Zhao H, Yan X, Li D, Wang B, Zhu L, Xu Y, et al. Mechanotransduction-modulated fibrotic microniches reveal the contribution of angiogenesis in liver fibrosis. Nat Mater. 2017;16(12):1252\u201361.","journal-title":"Nat Mater"},{"issue":"3","key":"1633_CR3","doi-asserted-by":"publisher","first-page":"377","DOI":"10.4254\/wjh.v7.i3.377","volume":"7","author":"GO Elpek","year":"2015","unstructured":"Elpek GO. Angiogenesis and liver fibrosis. World J Hepatol. 2015;7(3):377\u201391.","journal-title":"World J Hepatol"},{"issue":"19","key":"1633_CR4","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","volume":"64","author":"SM Wilhelm","year":"2004","unstructured":"Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al. BAY 43\u20139006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Can Res. 2004;64(19):7099\u2013109.","journal-title":"Can Res"},{"key":"1633_CR5","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.biopha.2017.01.107","volume":"88","author":"R Ma","year":"2017","unstructured":"Ma R, Chen J, Liang Y, Lin S, Zhu L, Liang X, Cai X. Sorafenib: A potential therapeutic drug for hepatic fibrosis and its outcomes. Biomed Pharmacother. 2017;88:459\u201368.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"1633_CR6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/biomedicines5020034","volume":"5","author":"M Rajabi","year":"2017","unstructured":"Rajabi M, Mousa SA. The Role of Angiogenesis in Cancer Treatment. Biomedicines. 2017;5(2):34.","journal-title":"Biomedicines"},{"issue":"6","key":"1633_CR7","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1158\/0008-5472.CAN-12-4697","volume":"73","author":"D Gerald","year":"2013","unstructured":"Gerald D, Chintharlapalli S, Augustin HG, Benjamin LE. Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy. Can Res. 2013;73(6):1649\u201357.","journal-title":"Can Res"},{"issue":"9","key":"1633_CR8","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1172\/JCI84923","volume":"126","author":"EA Korhonen","year":"2016","unstructured":"Korhonen EA, Lampinen A, Giri H, Anisimov A, Kim M, Allen B, Fang S, D\u2019Amico G, Sipila TJ, Lohela M, et al. Tie1 controls angiopoietin function in vascular remodeling and inflammation. J Clin Investig. 2016;126(9):3495\u2013510.","journal-title":"J Clin Investig"},{"issue":"9","key":"1633_CR9","doi-asserted-by":"publisher","first-page":"3511","DOI":"10.1172\/JCI84871","volume":"126","author":"M Kim","year":"2016","unstructured":"Kim M, Allen B, Korhonen EA, Nitschke M, Yang HW, Baluk P, Saharinen P, Alitalo K, Daly C, Thurston G, et al. Opposing actions of angiopoietin-2 on Tie2 signaling and FOXO1 activation. J Clin Investig. 2016;126(9):3511\u201325.","journal-title":"J Clin Investig"},{"issue":"2","key":"1633_CR10","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.canlet.2014.09.035","volume":"380","author":"NM Biel","year":"2016","unstructured":"Biel NM, Siemann DW. Targeting the Angiopoietin-2\/Tie-2 axis in conjunction with VEGF signal interference. Cancer Lett. 2016;380(2):525\u201333.","journal-title":"Cancer Lett"},{"issue":"2","key":"1633_CR11","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.lfs.2013.12.024","volume":"118","author":"F Rodriguez-Pascual","year":"2014","unstructured":"Rodriguez-Pascual F, Busnadiego O, Gonzalez-Santamaria J. The profibrotic role of endothelin-1: is the door still open for the treatment of fibrotic diseases? Life Sci. 2014;118(2):156\u201364.","journal-title":"Life Sci"},{"issue":"3","key":"1633_CR12","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1002\/hep.20828","volume":"42","author":"X Salcedo","year":"2005","unstructured":"Salcedo X, Medina J, Sanz-Cameno P, Garcia-Buey L, Martin-Vilchez S, Borque MJ, Lopez-Cabrera M, Moreno-Otero R. The potential of angiogenesis soluble markers in chronic hepatitis C. Hepatology (Baltimore, MD). 2005;42(3):696\u2013701.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"3","key":"1633_CR13","first-page":"1013","volume":"33","author":"T Mukozu","year":"2013","unstructured":"Mukozu T, Nagai H, Matsui D, Kanekawa T, Sumino Y. Serum VEGF as a tumor marker in patients with HCV-related liver cirrhosis and hepatocellular carcinoma. Anticancer Res. 2013;33(3):1013\u201321.","journal-title":"Anticancer Res"},{"issue":"6","key":"1633_CR14","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1111\/hepr.13490","volume":"50","author":"N Kawagishi","year":"2020","unstructured":"Kawagishi N, Suda G, Kimura M, Maehara O, Shimazaki T, Yamada R, Kitagataya T, Shigesawa T, Suzuki K, Nakamura A, Ohara M. High serum angiopoietin-2 level predicts non-regression of liver stiffness measurement-based liver fibrosis stage after direct-acting antiviral therapy for hepatitis C. Hepatol Res. 2020;50(6):671\u201381.","journal-title":"Hepatol Res"},{"issue":"44","key":"1633_CR15","doi-asserted-by":"publisher","first-page":"9744","DOI":"10.3748\/wjg.v22.i44.9744","volume":"22","author":"A Hernandez-Bartolome","year":"2016","unstructured":"Hernandez-Bartolome A, Lopez-Rodriguez R, Borque MJ, Gonzalez-Moreno L, Real-Martinez Y, Garcia-Buey L, Moreno-Otero R, Sanz-Cameno P. Angiopoietin-2\/angiopoietin-1 as non-invasive biomarker of cirrhosis in chronic hepatitis C. World J Gastroenterol. 2016;22(44):9744\u201351.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"1633_CR16","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/hep.30230","volume":"69","author":"AS Allegretti","year":"2019","unstructured":"Allegretti AS, Vela Parada X, Ortiz GA, Long J, Krinsky S, Zhao S, Fuchs BC, Sojoodi M, Zhang D, Karumanchi SA, et al. Serum angiopoietin-2 predicts mortality and kidney outcomes in decompensated cirrhosis. Hepatology (Baltimore, MD). 2019;69(2):729\u201341.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"3","key":"1633_CR17","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1002\/hep.29911","volume":"68","author":"F Faillaci","year":"2018","unstructured":"Faillaci F, Marzi L, Critelli R, Milosa F, Schepis F, Turola E, Andreani S, Vandelli G, Bernabucci V, Lei B, et al. Liver Angiopoietin-2 Is a Key Predictor of De Novo or Recurrent Hepatocellular Cancer After Hepatitis C Virus Direct-Acting Antivirals. Hepatology (Baltimore, MD). 2018;68(3):1010\u201324.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"1","key":"1633_CR18","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jhep.2016.07.009","volume":"66","author":"J Poisson","year":"2017","unstructured":"Poisson J, Lemoinne S, Boulanger C, Durand F, Moreau R, Valla D, Rautou PE. Liver sinusoidal endothelial cells: Physiology and role in liver diseases. J Hepatol. 2017;66(1):212\u201327.","journal-title":"J Hepatol"},{"issue":"5","key":"1633_CR19","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1002\/hep.27376","volume":"61","author":"LD DeLeve","year":"2015","unstructured":"DeLeve LD. Liver sinusoidal endothelial cells in hepatic fibrosis. Hepatology (Baltimore, MD). 2015;61(5):1740\u20136.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"5","key":"1633_CR20","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1053\/j.gastro.2008.07.065","volume":"135","author":"K Taura","year":"2008","unstructured":"Taura K, De Minicis S, Seki E, Hatano E, Iwaisako K, Osterreicher CH, Kodama Y, Miura K, Ikai I, Uemoto S, et al. Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis. Gastroenterology. 2008;135(5):1729\u201338.","journal-title":"Gastroenterology"},{"issue":"2","key":"1633_CR21","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/hep.510270222","volume":"27","author":"DC Rockey","year":"1998","unstructured":"Rockey DC, Fouassier L, Chung JJ, Carayon A, Vallee P, Rey C, Housset C. Cellular localization of endothelin-1 and increased production in liver injury in the rat: potential for autocrine and paracrine effects on stellate cells. Hepatology (Baltimore, MD). 1998;27(2):472\u201380.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"6","key":"1633_CR22","first-page":"552","volume":"16","author":"WS Moon","year":"2003","unstructured":"Moon WS, Rhyu KH, Kang MJ, Lee DG, Yu HC, Yeum JH, Koh GY, Tarnawski AS. Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma? Mod Pathol Offic J US Can Acad Pathol. 2003;16(6):552\u20137.","journal-title":"Mod Pathol Offic J US Can Acad Pathol"},{"issue":"3","key":"1633_CR23","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.jhep.2016.04.018","volume":"65","author":"G Marrone","year":"2016","unstructured":"Marrone G, Shah VH, Gracia-Sancho J. Sinusoidal communication in liver fibrosis and regeneration. J Hepatol. 2016;65(3):608\u201317.","journal-title":"J Hepatol"},{"issue":"1","key":"1633_CR24","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.jhep.2010.02.027","volume":"53","author":"Y Wang","year":"2010","unstructured":"Wang Y, Gao J, Zhang D, Zhang J, Ma J, Jiang H. New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis. J Hepatol. 2010;53(1):132\u201344.","journal-title":"J Hepatol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-021-01633-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12876-021-01633-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-021-01633-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T17:55:52Z","timestamp":1612806952000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-021-01633-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,8]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1633"],"URL":"https:\/\/doi.org\/10.1186\/s12876-021-01633-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-92848\/v1","asserted-by":"object"}]},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,8]]},"assertion":[{"value":"28 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All analyses using human samples were approved by the institutional research ethics committee at NCGM Kohnodai Hospital (NCGM-G-001967-04 and NCGM-G-003231-00). Written informed consent was obtained from all patients. All animal experiments were conducted in accordance with institutional guidelines (Guide for the Care and Use of Laboratory Animals prepared by the National Academy of Sciences), act on welfare and management of animals (Act No. 46 of May 30, 2014, Japanese low), and standards relating to the care and keeping and reducing pain of laboratory animals (notice of the Japanese ministry of the environment, NO88 of 2006) and the protocol was approved by the Animal Research Committee of the National Center for Global Health and Medicine (Nos. 20555 and 20056).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Tatsuya Kanto received honoraria from Gilead Sciences, MSD, and Abbie.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"55"}}